Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Reviewing Cancer Trial Endpoints, Oncology Director Pazdur Tells ASCO

Executive Summary

FDA's Division of Oncologic Drug Products will conduct an internal review of regulatory endpoints for cancer trials, division Director Richard Pazdur, MD, said May 13 during the American Society of Clinical Oncology annual meeting in San Francisco.

You may also be interested in...



Cancer Survival And Symptom Trials May Be "Ideal Drug Package" - Pazdur

Submission of one cancer survival trial and one symptom trial for approval of oncologic agents would be considered optimal by FDA, Oncologic Drug Products Division Director Richard Pazdur, MD, said.

Cancer Survival And Symptom Trials May Be "Ideal Drug Package" - Pazdur

Submission of one cancer survival trial and one symptom trial for approval of oncologic agents would be considered optimal by FDA, Oncologic Drug Products Division Director Richard Pazdur, MD, said.

Roche Xeloda Colorectal Use Clears FDA; Promotions Must Cite Camptosar

Roche will study Xeloda in combination with Pharmacia's Camptosar in colorectal cancer patients following FDA approval of Xeloda April 30 for use in metastatic colorectal cancer patients.

UsernamePublicRestriction

Register

PS037860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel